<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21360159</article-id><article-id pub-id-type="pmc">3072486</article-id><article-id pub-id-type="publisher-id">312</article-id><article-id pub-id-type="doi">10.1007/s10194-011-0312-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tfelt-Hansen</surname><given-names>Peer</given-names></name><address><email>ptha@glo.regionh.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Neurology, Danish Headache Centre, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2011</year></pub-date><volume>12</volume><issue>2</issue><fpage>269</fpage><lpage>270</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>2</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>To the Editor,</p><p>Aspirin plus metoclopramide, an antiemetic and prokinetic drug, for acute migraine treatment was introduced by Marcia Wilkinson at The City of London Migraine Clinic [<xref ref-type="bibr" rid="CR1">1</xref>] and until the advent of sumatriptan, it was in several countries the standard treatment for migraine, see [<xref ref-type="bibr" rid="CR2">2</xref>]. Sumatriptan, subcutaneous 6&#x000a0;mg and oral 100&#x000a0;mg, was introduced in 1991 [<xref ref-type="bibr" rid="CR3">3</xref>]. Subcutaneous sumatriptan 6&#x000a0;mg resulted in headache relief (HR) (a decrease of headache from moderate or severe to none or mild) in 70&#x02013;72% after 1&#x000a0;h [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and 86% after 2&#x000a0;h [<xref ref-type="bibr" rid="CR4">4</xref>].Oral sumatriptan 100&#x000a0;mg (56% HR) was not superior to the oral combination of aspirin 1,000&#x000a0;mg and metoclopramide (ASP&#x000a0;+&#x000a0;M)10&#x000a0;mg (45%) in the first attack treated, but sumatriptan was better than the combination in the second and third attack [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>From 1993 to 1994, a randomised, controlled trial (RCT) was performed in France. It had the title: &#x0201c;A randomised, multicentre, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of subcutaneous sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine&#x0201d; [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>It was performed in 46 centres in France and showed, as expected, that subcutaneous sumatriptan 6&#x000a0;mg was superior (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) to efferverscent aspirin 1,000&#x000a0;mg plus metoclopramide 10&#x000a0;mg from 30 to 120&#x000a0;min, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Subcutaneous sumatriptan 6&#x000a0;mg was successful in 84% of patients at 2&#x000a0;h and similar results were reported in one pivotal RCT (86%) on subcutaneous sumatriptan [<xref ref-type="bibr" rid="CR4">4</xref>]. The headache relief for ASP&#x000a0;+&#x000a0;M was 62% and somewhat higher than the 45% observed in a comparative RCT [<xref ref-type="bibr" rid="CR6">6</xref>], see above, but in the range of the 56% headache relief observed in two other RCTs, with highly soluble lysine acetylsalicylate plus metoclopramide [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The relative high-headache response for ASA&#x000a0;+&#x000a0;M could be due to the use of effervescent aspirin [<xref ref-type="bibr" rid="CR7">7</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Headache relief (HR) and therapeutic gain (percentage HR after subcutaneous sumatriptan 6&#x000a0;mg minus percentage HR after effervescent aspirin 1,000&#x000a0;mg plus metoclopramide) for the first-treated migraine attack</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Sumatriptan (<italic>n</italic>&#x000a0;=&#x000a0;122)</th><th align="left">ASP&#x000a0;+&#x000a0;M (<italic>n</italic>&#x000a0;=&#x000a0;125)</th></tr></thead><tbody><tr><td align="left">Headache relief after 30&#x000a0;min</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">62 (50%)</td><td char="." align="char">31 (24%)</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">62 (50%)</td><td char="." align="char">96 (76%)</td></tr><tr><td align="left" colspan="3"><italic>Therapeutic gain 26% (95% CI 14&#x02013;37%)</italic></td></tr><tr><td align="left" colspan="3">Headache relief after 60&#x000a0;min</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">87 (71%)</td><td char="." align="char">57 (45%)</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">35 (29%)</td><td char="." align="char">69 (55%)</td></tr><tr><td align="left" colspan="3"><italic>Therapeutic gain 26% (95% CI 14&#x02013;38%)</italic></td></tr><tr><td align="left" colspan="3">Headache relief after 120&#x000a0;min</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">99 (84%)</td><td char="." align="char">79 (62%)</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">19 (16%)</td><td char="." align="char">48 (38%)</td></tr><tr><td align="left" colspan="3"><italic>Therapeutic gain 22% (95% CI 11&#x02013;32%)</italic></td></tr></tbody></table></table-wrap></p><p>The rationale for doing this RCT remains obscure. Why should an injection of an antimigraine drug (the optimal route of administration) be compared with an oral form of another antimigraine drug (a suboptimal form because of slower absorption)? The most likely reason is that this RCT was done solely for registration purposes in France. We don&#x02019;t know whether it was done at the request of the French health authorities. Any way, this RCT, even if based only on the summary, was of good quality and the RCT remains unpublished 17&#x000a0;years later. Publication is an obligation of the clinical investigators [<xref ref-type="bibr" rid="CR10">10</xref>] and this RCT should have been published many years ago.</p></body><back><ack><title>Conflict of interest</title><p>None.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>M</given-names></name></person-group><article-title>Editorial: the treatment of acute migraine attacks</article-title><source>Headache</source><year>1976</year><volume>15</volume><fpage>291</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1976.hed1504291.x</pub-id><pub-id pub-id-type="pmid">1245412</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Aebelholt</surname><given-names>A</given-names></name><name><surname>Veilis</surname><given-names>B</given-names></name></person-group><article-title>The Copenhagen acute headache clinic: organization, patient material and treatment results</article-title><source>Headache</source><year>1979</year><volume>19</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1979.hed1904223.x</pub-id><pub-id pub-id-type="pmid">36364</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humhrey</surname><given-names>PP</given-names></name></person-group><article-title>The discovery and development of the triptans: a major therapeutic breakthrough</article-title><source>Headache</source><year>2008</year><volume>48</volume><fpage>685</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01097.x</pub-id><pub-id pub-id-type="pmid">18471110</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Subcutaneous Sumatriptan International Study Group</collab></person-group><article-title>Treatment of migraine attacks with sumatriptan</article-title><source>N Engl J Med</source><year>1991</year><volume>325</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1056/NEJM199108013250504</pub-id><pub-id pub-id-type="pmid">1647495</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cady</surname><given-names>RK</given-names></name><name><surname>Wendt</surname><given-names>JK</given-names></name><name><surname>Kirchner</surname><given-names>JR</given-names></name><name><surname>Sargent</surname><given-names>JD</given-names></name><name><surname>Rothrock</surname><given-names>JF</given-names></name><name><surname>Skaggs</surname><given-names>H</given-names><suffix>Jr</suffix></name></person-group><article-title>Treatment of acute migraine with subcutaneous sumatriptan</article-title><source>JAMA</source><year>1991</year><volume>265</volume><fpage>2831</fpage><lpage>2835</lpage><pub-id pub-id-type="doi">10.1001/jama.265.21.2831</pub-id><pub-id pub-id-type="pmid">1851894</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group</collab></person-group><article-title>A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine</article-title><source>Eur Neurol</source><year>1992</year><volume>32</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1159/000116818</pub-id><pub-id pub-id-type="pmid">1317294</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Study no.: S2BL99. A randomised, multicentre, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of subcutaneous sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. <ext-link ext-link-type="uri" xlink:href="http://www.gsk-clinicalstudyregister.com">www.gsk-clinicalstudyregister.com</ext-link>. Assessed October 2010</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chabriat</surname><given-names>H</given-names></name><name><surname>Joire</surname><given-names>JE</given-names></name><name><surname>Danchot</surname><given-names>J</given-names></name><name><surname>Grippon</surname><given-names>P</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name></person-group><article-title>Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study</article-title><source>Cephalalgia</source><year>1994</year><volume>14</volume><fpage>297</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1994.1404297.x</pub-id><pub-id pub-id-type="pmid">7954760</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Henry</surname><given-names>P</given-names></name><name><surname>Mulder</surname><given-names>K</given-names></name><name><surname>Scheldewaert</surname><given-names>RG</given-names></name><name><surname>Schoenen</surname><given-names>J</given-names></name><name><surname>Chazot</surname><given-names>G</given-names></name></person-group><article-title>The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>923</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)91554-0</pub-id><pub-id pub-id-type="pmid">7564725</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Ethics Subcommittee of the International Headache Society</collab></person-group><article-title>Ethical issues in headache research and management</article-title><source>Cephalalgia</source><year>1998</year><volume>18</volume><fpage>505</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1998.1807505.x</pub-id><pub-id pub-id-type="pmid">11645127</pub-id></mixed-citation></ref></ref-list></back></article>